NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
Clinical Trials
8 trialsNCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06008119 2025-09-18
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Shanghai Kechow Pharma, Inc.
Phase 3 Recruiting
NCT02908672 2025-07-20
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche
Phase 3 Completed
NCT01689519 2022-05-02
coBRIM
Hoffmann-La Roche
Phase 3 Completed
NCT01667419 2019-07-23
BRIM8
Hoffmann-La Roche
Phase 3 Completed
NCT02427893 2016-11-15
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 3 Withdrawn
NCT01006980 2016-09-28
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Hoffmann-La Roche
Phase 3 Completed